Trials / Completed
CompletedNCT03351738
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease
A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease.
Detailed description
A Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Participants with Stable Coronary Heart Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI5884 | Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61. |
| DRUG | Placebo | Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61. |
Timeline
- Start date
- 2017-12-13
- Primary completion
- 2018-11-09
- Completion
- 2018-11-09
- First posted
- 2017-11-24
- Last updated
- 2020-03-23
- Results posted
- 2019-12-19
Locations
23 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03351738. Inclusion in this directory is not an endorsement.